{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T18:57:48Z","timestamp":1754161068005,"version":"3.41.2"},"reference-count":23,"publisher":"Vilnius University Press","issue":"1","license":[{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AML"],"abstract":"<jats:p>Background:\u00a0Chemotherapy-induced nausea and vomiting (CINV) is a significant concern for patients undergoing highly emetogenic chemotherapy (HEC). This study compares the efficacy of aprepitant and olanzapine in preventing CINV in breast cancer patients receiving Adriamycin and Cyclophosphamide (AC).Methods:\u00a0A prospective, comparative, observational study was conducted over one year at the State Cancer Institute, Guwahati, India. 103 chemotherapy-na\u00efve breast cancer patients were enrolled and divided into two groups: aprepitant and olanzapine, both receiving standard therapy with ondansetron and dexamethasone. CINV outcomes were assessed using the Multinational Association of Supportive Care in Cancer (MASCC) Antiemesis Tool over five days post-chemotherapy. Acute (0\u201324 hours) and delayed (24\u2013120 hours) nausea and vomiting were evaluated. Side effects were documented and compared between groups.Results:\u00a0Olanzapine demonstrated significantly better control of acute nausea compared to aprepitant (p\u00a0&lt; 0.05). It also showed a trend towards superior efficacy in delayed nausea, though statistical significance was not reached. There was no significant difference between aprepitant and olanzapine in preventing acute or delayed vomiting. The olanzapine group experienced more frequent side effects, but the difference was statistically insignificant.Conclusion:\u00a0Olanzapine exhibited greater efficacy in preventing nausea, particularly in the acute phase, compared to aprepitant. However, its higher side effect profile suggests that careful patient selection is necessary. Both agents remain effective options for CINV management, with olanzapine offering an advantage in nausea prevention.<\/jats:p>","DOI":"10.15388\/amed.2025.32.1.22","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T02:15:18Z","timestamp":1749435318000},"page":"118-125","source":"Crossref","is-referenced-by-count":0,"title":["Aprepitant versus Olanzapine in Patients of Breast Cancer on Adriamycin and Cyclophosphamide Regimen \u2013 Role in Effectiveness of Prevention of Nausea and Vomiting"],"prefix":"10.15388","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6211-5398","authenticated-orcid":false,"given":"Indrani Devi","family":"Sarma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3457-374X","authenticated-orcid":false,"given":"Sukainnya","family":"Buragohain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9937-1789","authenticated-orcid":false,"given":"Joonmoni","family":"Lahon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Indrani","family":"Bhagawati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neelakshi","family":"Mahanta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dibyajyoti","family":"Saikia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6097","published-online":{"date-parts":[[2025,6,9]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Mehrotra R, Yadav K. Breast cancer in India: Present scenario and the challenges ahead. World J Clin Oncol. 2022;13(3):209-218. doi:10.5306\/wjco.v13.i3.209","DOI":"10.5306\/wjco.v13.i3.209"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Steponavi\u010dien\u0117 L, Briedien\u0117 R, Vansevi\u010di\u016bt\u0117-Petkevi\u010dien\u0117 R, Gudavi\u010dien\u0117 D, Vincer\u017eevskien\u0117 I. Breast cancer screening program in Lithuania: trends in breast cancer mortality before and during the introduction of the mammography screening programme. Acta Med Litu. 2020;27(2):61-69. doi:10.15388\/Amed.2020.27.2.3","DOI":"10.15388\/Amed.2020.27.2.3"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Vincer\u017eevskien\u0117 I, Krilavi\u010di\u016bt\u0117 A, Smailyt\u0117 G. Trends in cancer incidence in Lithuania between 1991 and 2010. Acta Med Litu. 2014;20(4):135-146. doi:10.6001\/actamedica.v20i4.2811","DOI":"10.6001\/actamedica.v20i4.2811"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Li Q, Wu Y, Wang W, et al. Effectiveness and safety of combined neurokinin-1 antagonist Aprepitant treatment for multiple-day anthracycline-induced nausea and vomiting. Curr Probl Cancer. 2019;43(6):100462. doi:10.1016\/j.currproblcancer.2019.01.003","DOI":"10.1016\/j.currproblcancer.2019.01.003"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Dando TM, Perry CM. Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs. 2004;64(7):777-794. doi:10.2165\/00003495-200464070-00013","DOI":"10.2165\/00003495-200464070-00013"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Bosnjak SM, Dimitrijevic J, Djordjevic F. Cancer and chemotherapy-induced nausea and vomiting: a focus on Olanzapine. Curr Opin Support Palliat Care. 2016;10(2):180-188. doi:10.1097\/SPC.0000000000000206","DOI":"10.1097\/SPC.0000000000000206"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Molassiotis A, Coventry PA, Stricker CT, et al. Validation and psychometric assessment of a short clinical scale to measure chemotherapy-induced nausea and vomiting: the MASCC antiemesis tool. J Pain Symptom Manage. 2007;34(2):148-159. doi:10.1016\/j.jpainsymman.2006.10.018","DOI":"10.1016\/j.jpainsymman.2006.10.018"},{"key":"ref7","unstructured":"National Cancer Institute. Protocol Development | CTEP [Internet]. Cancer.gov; 2017. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Wang C, Jiang Z, Zhang J, et al. Prolonged administration of the granisetron transdermal delivery system reduces capecitabine plus oxaliplatin regimen induced nausea and vomiting. BMC Cancer. 2024;24(1):867. doi:10.1186\/s12885-024-12616-9","DOI":"10.1186\/s12885-024-12616-9"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol. 2011;9(5):188-195. doi:10.1016\/j.suponc.2011.05.002","DOI":"10.1016\/j.suponc.2011.05.002"},{"key":"ref10","unstructured":"Kane SP. Sample Size Calculator. ClinCalc. Updated June 23, 2024. Accessed April 1, 2025. https:\/\/clincalc.com\/stats\/samplesize.aspx"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Zhang XL, Ying JE. Olanzapine for the Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting: A Review to Identify the Best Way to Administer the Drug. Curr Oncol. 2022;29(11):8235-8243. doi:10.3390\/curroncol29110650","DOI":"10.3390\/curroncol29110650"},{"key":"ref12","unstructured":"Ibrahim MA, Pellegrini MV, Preuss CV. Antiemetic Neurokinin-1 Receptor Blockers. In: StatPearls. Treasure Island: StatPearls Publishing; January 11, 2024. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK470394\/"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Babu G, Saldanha SC, Kuntegowdanahalli Chinnagiriyappa L, et al. The Efficacy, Safety, and Cost Benefit of Olanzapine versus Aprepitant in Highly Emetogenic Chemotherapy: A Pilot Study from South India. Chemother Res Pract. 2016;2016:3439707. doi:10.1155\/2016\/3439707","DOI":"10.1155\/2016\/3439707"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Navari RM, Roeland EJ. Unscheduled hydrations: redefining complete response in chemotherapy-induced nausea and vomiting studies. Future Oncol. 2020;16(24):1863-1872. doi:10.2217\/fon-2020-0452","DOI":"10.2217\/fon-2020-0452"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Navari RM, Qin R, Ruddy KJ, et al. Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med. 2016;375(2):134-142. doi:10.1056\/NEJMoa1515725","DOI":"10.1056\/NEJMoa1515725"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Hussein AM, Yasin JA, Abdullah Yousef Aldalati, et al. Olanzapine for the Prevention of Postoperative Nausea and Vomiting: An Updated Meta-Analysis with Trial Sequential Analysis. Journal of Pain and Symptom Management. 2025;69(5):e359-e373. doi:10.1016\/j.jpainsymman.2025.02.003","DOI":"10.1016\/j.jpainsymman.2025.02.003"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Chow R, Herrstedt J, Aapro M, et al. Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature. Support Care Cancer. 2021;29(7):3439-3459. doi:10.1007\/s00520-020-05935-7","DOI":"10.1007\/s00520-020-05935-7"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Zhang Z, Zhang Y, Chen G, et al. Olanzapine-Based Triple Regimens Versus Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy: A Network Meta-Analysis. Oncologist. 2018;23(5):603-616. doi:10.1634\/theoncologist.2017-0378","DOI":"10.1634\/theoncologist.2017-0378"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Osman AAM, Elhassan MMA, AbdElrahim BHA, et al. Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Comparative Study from Sudan. J Glob Oncol. 2018;4:1-9. doi:10.1200\/JGO.17.00216","DOI":"10.1200\/JGO.17.00216"},{"key":"ref20","unstructured":"Thomas K, Saadabadi A. Olanzapine. In: StatPearls [Internet]. Treasure Island: StatPearls Publishing; 2023. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK532903\/"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Chiu L, Chow R, DeAngelis C, Lock M, Simone CB 2nd. Secondary and cumulative meta-analysis of Olanzapine for antiemetic prophylaxis for chemotherapy-induced nausea and vomiting: do we still need to study its effectiveness?. Ann Palliat Med. 2021;10(3):2540-2547. doi:10.21037\/apm-20-1462","DOI":"10.21037\/apm-20-1462"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Chelkeba L, Gidey K, Mamo A, Yohannes B, Matso T, Melaku T. Olanzapine for chemotherapy-induced nausea and vomiting: systematic review and meta-analysis. Pharm Pract (Granada). 2017;15(1):877. doi:10.18549\/PharmPract.2017.01.877","DOI":"10.18549\/PharmPract.2017.01.877"}],"container-title":["Acta medica Lituanica"],"original-title":[],"link":[{"URL":"https:\/\/www.zurnalai.vu.lt\/AML\/article\/download\/38736\/39565","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journals.vu.lt\/AML\/article\/download\/38736\/39566","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.zurnalai.vu.lt\/AML\/article\/download\/38736\/39566","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.zurnalai.vu.lt\/AML\/article\/download\/38736\/39565","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T12:04:22Z","timestamp":1753704262000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.zurnalai.vu.lt\/AML\/article\/view\/38736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,9]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,2,18]]}},"URL":"https:\/\/doi.org\/10.15388\/amed.2025.32.1.22","relation":{},"ISSN":["2029-4174","1392-0138"],"issn-type":[{"type":"electronic","value":"2029-4174"},{"type":"print","value":"1392-0138"}],"subject":[],"published":{"date-parts":[[2025,6,9]]}}}